Browsing Clinical Studies by author "Furness, Andrew"
Now showing items 1-15 of 15
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27)Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients ... -
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas, F; Furness, AJS; Litchfield, K; Joshi, K; Rosenthal, R; et al. (CELL PRESS, 2018-04-09)With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion ... -
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas, F; Furness, AJS; Solomon, I; Joshi, K; Mekkaoui, L; et al. (CELL PRESS, 2017-04-18)CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We ... -
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-09-20)Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were ... -
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Fendler, A; Shepherd, STC; Au, L; Wu, M; Harvey, R; et al. (CELL PRESS, 2022-10-18)Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we ... -
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; et al. (CELL PRESS, 2019-06-26)Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ... -
Immunotherapy of sarcomas with modified T cells.
Mahalingam, P; Julve, M; Huang, P; Furness, AJS; Pollack, SM; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-07-01)PURPOSE OF REVIEW: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. RECENT FINDINGS: Numerous clinical trials are underway evaluating ... -
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-03)Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ... -
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
Litchfield, K; Reading, JL; Puttick, C; Thakkar, K; Abbosh, C; et al. (CELL PRESS, 2021-02-04)Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features underpinning CPI sensitization. Here, we ... -
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Wu, MY; Shepherd, STC; Fendler, A; Carr, EJ; Au, L; et al. (CELL PRESS, 2023-05-08)Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants. -
Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study.
Fu, X; Zhao, Y; Lopez, JI; Rowan, A; Au, L; et al. (NATURE PORTFOLIO, 2022-01-01)Genetic intra-tumour heterogeneity fuels clonal evolution, but our understanding of clinically relevant clonal dynamics remain limited. We investigated spatial and temporal features of clonal diversification in clear cell ... -
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
Wilkins, A; Furness, A; Corbett, RW; Bloomfield, A; Porta, N; et al. (NATURE PUBLISHING GROUP, 2015-11-03)BACKGROUND: The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups. It was largely derived using clinical data from patients ... -
The role of systemic therapy in paediatric cutaneous melanoma: a review
Chisholm, J; Corley, E; Furness, A; Schmitt, A -
'You give me fever!': are health services ready for immune cell engager therapy in advanced solid malignancies?
Pettinger, C; Livings, C; Grochot, R; Furness, A; Lopez, J (BMJ PUBLISHING GROUP, 2022-12-01)Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets ...